U.S. License Holder:
Ablynx NV
Date of License:
February-06-2019
Last Update:
Sep-30-2024
FDA-Approved Indications
CABLIVI (caplacizumab-yhdp) is a von Willebrand factor (vWF)-directed antibody fragment indicated for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.